Welcome to Grünenthal. This site uses cookies. Read our policy.

Accept Cookies

Innovation &

Finding solutions that improve patients’ lives


We aim to deliver major therapeutic advances by treating patients with a high burden of disease, offering clear benefits for patients and sound health economics for society. Our exciting R&D pipeline includes several new drug candidates and technologies to improve patients’ lives.

At Grünenthal, there is close collaboration between all stakeholders involved in research, and each is equally important. Our networked approach to R&D means that we can interlink and supplement our own expertise with external knowledge, leading to improved outcomes.

Fueling our pipeline with innovation

Latest Updates

CGRP Antibodies in Migraine

Calcitonin gene-related peptide (CGRP)-targeted antibodies represent the first in a new class of drugs designed for the preventive treatment of migraine in adults. Following the recent FDA approval in this drug group, we review the pathophysiology of migraine and how these novel treatments can revolutionise prevention of this debilitating condition.

... Discover more

IMI-PainCare Initiative

The Innovative Medicines Initiative (IMI) PainCare initiative is a consortium composed of 40 participants from 14 countries, co-led by Grünenthal and the University of Heidelberg. The three sub-projects, PROMPT, BioPain and TRiPP, aim to revolutionise different aspects of pain research and development, and pain management with the aim of improving the care of patients suffering from acute or chronic pain.

... Discover more

Re-defining pain through patient-inspired R&D

... Discover more

Placebo Effect and Pain – Part 3

In this latest article on the placebo effect and pain, we look at the findings from a recently published trial supported by Grünenthal that shows promise for reducing the likelihood of clinical trial failure due to variations and bias in symptom reporting by participants. The background to this study and its implications are discussed.

... Discover more


Share this with:

These are external links and will open in a new window